Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:1219:355-363.
doi: 10.1007/978-3-030-34025-4_18.

Ovarian Cancer Biomarkers: Moving Forward in Early Detection

Vasco D B Bonifácio  1
Affiliations
Review

Ovarian Cancer Biomarkers: Moving Forward in Early Detection

Vasco D B Bonifácio. Adv Exp Med Biol. 2020.

Abstract

Ovarian cancer is a silent cancer which rate survival mainly relays in early stage detection. The discovery of reliable ovarian cancer biomarkers plays a crucial role in the disease management and strongly impact in patient's prognosis and survival. Although having many limitations CA125 is a classical ovarian cancer biomarker, but current research using proteomic or metabolomic methodologies struggles to find alternative biomarkers, using non-invasive our relatively non-invasive sources such as urine, serum, plasma, tissue, ascites or exosomes. Metabolism and metabolites are key players in cancer biology and its importance in biomarkers discovery cannot be neglected. In this chapter we overview the state of art and the challenges facing the use and discovery of biomarkers and focus on ovarian cancer early detection.

Keywords: Cancer biomarkers; Early detection; Metabolomics; Ovarian cancer; Proteomics; Urine biomarkers.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S, Smith AI, Kemp BE, Quinn MA, Rice GE (2004) Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91:129–140 - PubMed - PMC - DOI
    1. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE (2005) Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5:4625–4636 - PubMed - DOI
    1. Akinyemiju T, Moore JX, Judd SE, Pisu M, Goodman M, Howard VJ, Long L, Safford M, Gilchrist SC, Cushman M (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099–16109 - PubMed - PMC - DOI
    1. An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang S, Ding B, Cho NH (2006) Comparative proteomics of ovarian epithelial tumors. J Proteome Res 5:1082–1090 - PubMed - DOI
    1. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867 - PubMed - DOI

LinkOut - more resources